Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAE125
- Development stage
- Preclinical
- Lead developer
- Laekna
- Administration
- Intravenous, Subcutaneous
01
Overview
LAE125 is a preclinical drug candidate being developed by Laekna for the treatment of obesity. It targets the apelin pathway, which involves the apelin receptor (APJ or APLNR), a G protein-coupled receptor that is widely expressed in tissues relevant to metabolic health, including the hypothalamus, adipose tissue, and the cardiovascular system. The apelin-APJ system is an endogenous signaling pathway that plays a significant role in regulating energy metabolism, insulin sensitivity, and fluid homeostasis. By modulating this pathway, LAE125 is intended to address metabolic dysregulation and facilitate weight management in patients with obesity.
02
Targets
APLNR (Apelin receptor)
Beyond the preview
Go deeper on LAE125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAE125.